Chronic Obstructive Pulmonary Disease News and Research

Latest Chronic Obstructive Pulmonary Disease News and Research

DRIVE4COPD initiative aims to raise awareness of COPD

In just four months since its launch, DRIVE4COPD has already encouraged more than 100,000 people to be screened to see if they may be at risk for chronic obstructive pulmonary disease. The country's newest health initiative that aims to raise awareness of COPD in the hopes that people will talk to their doctor and get diagnosed instead of suffering in silence. Currently, half of the estimated 24 million Americans who may have COPD remain undiagnosed and untreated, and most are not diagnosed until they have lost half their lung function.

11 Jun 2010

Centocor Ortho Biotech acquires RespiVert

Centocor Ortho Biotech Inc. today announced that it has acquired RespiVert Ltd., a privately held drug discovery company focused on developing small-molecule, inhaled therapies for the treatment of pulmonary diseases. The company's lead compounds, RV-568 and RV-1088, narrow spectrum kinase inhibitors with a unique profile of anti-inflammatory activities, are progressing into clinical development as potential first-in-class treatments for moderate to severe asthma, Chronic Obstructive Pulmonary Disease (COPD) and Cystic Fibrosis (CF).

1 Jun 2010

Wireless monitoring system for people with debilitating conditions

A wireless monitoring system for people with debilitating conditions such as Parkinson's disease or chronic obstructive pulmonary disorder could allow healthcare workers to assess a patient's health and the development of their disease without hindering their movements. Details of the system are reported in the International Journal of Biomedical Engineering and Technology.

27 May 2010

Amira announces UK patent grant for heteroalkyl antagonists of prostaglandin D2 receptors

Amira Pharmaceuticals, Inc. today announced that the U.K. Intellectual Property Office has granted patent number GB2461629, titled, "HETEROALKYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS," which includes coverage of Amira's AM461 DP2 receptor antagonist.

27 May 2010

Intel expands availability of Intel Health Guide across Europe

Intel is expanding availability of the Intel Health Guide across Europe to help address chronic care challenges - Intel is working with strategic partners in France, Germany, Spain and The Netherlands to bring localised versions of the Intel Health Guide to market over the coming year

26 May 2010

Researchers examine association between use of antibiotics and outcomes among patients with COPD

Among patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease, those who received antibiotics in the first 2 hospital days had improved outcomes, such as a lower likelihood of mechanical ventilation and fewer readmissions, compared to patients who received antibiotics later or not at all, according to a study in the May 26 issue of JAMA.

26 May 2010

Beta-blocker medications provide new hope for patients with COPD: Study

Patients with chronic obstructive pulmonary disease may have fewer respiratory flare-ups and longer survival if they take beta-blocker medications, according to a report in the May 24 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

25 May 2010

Ectoin shows positive effect on nanoparticle-induced lung inflammation: Study

bitop AG, which specializes in the development and marketing of Ectoin-containing medical devices, announces that Ectoin significantly reduces nanoparticle-induced inflammatory reaction in rat lungs, one of the animal models for chronic obstructive pulmonary disease. It is the first time that Ectoin has been shown to have such an effect on nanoparticle-induced lung inflammation.

20 May 2010

People with asthma or COPD at risk from oil-dispersing chemicals

Oil washing ashore and the chemicals used in the clean up may pose a health risk for those who have respiratory diseases according to an environmental allergy-asthma expert.

19 May 2010

Pearl Therapeutics presents data supporting development of PT003 combination bronchodilator product

Pearl Therapeutics Inc., a company developing clinically differentiated double and triple combination therapies for the treatment of highly prevalent chronic respiratory diseases, presented results from four studies that provide support for further development of PT003, the company's fixed dose combination of glycopyrrolate and formoterol delivered via a pressurized hydrofluoroalkane metered dose inhaler (HFA-MDI).

19 May 2010

Breathe Technologies to fund commercialization of mobile ventilation system with $23M Series C financing

Breathe Technologies, Inc., a manufacturer of innovative technology solutions for people with respiratory conditions, including chronic obstructive pulmonary disease and sleep apnea, announced today it has secured $23 million in Series C financing.

19 May 2010

Study confirms genetic overlap for susceptibility to COPD and lung cancer

New research shows genes that make smokers more likely to develop chronic obstructive pulmonary disease (COPD), or emphysema, are also closely linked to an increased likelihood of developing lung cancer, according to studies presented today at the American Thoracic Society's annual meeting.

18 May 2010

Pfizer, Washington University announce indications discovery collaboration

In a first-of-a-kind collaboration between academia and industry, Pfizer Inc. will give scientists at Washington University School of Medicine in St. Louis unprecedented access to information regarding more than 500 pharmaceuticals and pharmaceutical candidates in a partnership that focuses on discovering new uses for existing compounds.

18 May 2010

NMES may reduce muscle atrophy in patients with severe COPD: Researchers

Neuromuscular electrical stimulation may reduce muscle atrophy in patients with severe chronic obstructive pulmonary disease, according to Canadian researchers.

18 May 2010

Obese patients with COPD improve following pulmonary rehabilitation program: Research

Obese patients with chronic obstructive pulmonary disease stand to gain as much from pulmonary rehabilitation as their slimmer counterparts, even though as a group they have a lower exercise capacity, according to new research from the University Hospitals of Leicester in the UK.

17 May 2010

Long-term, regular use of vitamin E in women may help decrease risk of COPD: Study

Long-term, regular use of vitamin E in women 45 years of age and older may help decrease the risk of chronic obstructive pulmonary disease by about 10 percent in both smokers and non-smokers, according to a study conducted by researchers at Cornell University and Brigham and Women's Hospital.

17 May 2010

Researchers discover molecular mechanism behind smoking cessation effect

The tobacco addiction epidemic is a major public health problem worldwide. Professor Zhao Baolu and his group from the State Key Laboratory of Brain and Cognitive Science, Institute of Biophysics, Chinese Academy of Sciences set out to tackle this problem. After 20 years of innovative research, they have developed a novel tea filter to treat cigarette addiction and have discovered the molecular mechanism behind the smoking cessation effect.

12 May 2010

MediciNova announces $15 million senior secured term loan with Oxford Finance

MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market and the Hercules Market of the Osaka Securities Exchange, today announced that it has entered into a $15 million senior secured term loan with Oxford Finance Corporation.

11 May 2010

Forest, Almirall to present data on aclidinium bromide for COPD and LAS100977 for asthma at ATS conference

Forest Laboratories, Inc. and Almirall, S.A. today announced that they are presenting data from several studies of two investigational inhaled respiratory compounds at the annual American Thoracic Society International Conference taking place in New Orleans May 14-19, 2010. Data on aclidinium bromide, an inhaled muscarinic antagonist, which is in Phase III development for COPD, and LAS100977, a long-acting beta 2-agonist, in Phase II development for asthma, will be presented in 11 separate posters.

11 May 2010

Forest, Nycomed to present data from six roflumilast posters at ATS International Conference

Forest Laboratories, Inc. and Nycomed today announced that they will present data from six roflumilast posters during the American Thoracic Society (ATS) International Conference being held in New Orleans, LA, May 14 through May 19, 2010. Roflumilast is an investigational anti-inflammatory, oral medication for the treatment of Chronic Obstructive Pulmonary Disease (COPD) associated with chronic bronchitis in patients at risk of exacerbations.

10 May 2010

Chronic Obstructive Pulmonary Disease News and Research

Latest Chronic Obstructive Pulmonary Disease News and Research

DRIVE4COPD initiative aims to raise awareness of COPD

Centocor Ortho Biotech acquires RespiVert

Wireless monitoring system for people with debilitating conditions

Amira announces UK patent grant for heteroalkyl antagonists of prostaglandin D2 receptors

Intel expands availability of Intel Health Guide across Europe

Researchers examine association between use of antibiotics and outcomes among patients with COPD

Beta-blocker medications provide new hope for patients with COPD: Study

Ectoin shows positive effect on nanoparticle-induced lung inflammation: Study

People with asthma or COPD at risk from oil-dispersing chemicals

Pearl Therapeutics presents data supporting development of PT003 combination bronchodilator product

Breathe Technologies to fund commercialization of mobile ventilation system with $23M Series C financing

Study confirms genetic overlap for susceptibility to COPD and lung cancer

Pfizer, Washington University announce indications discovery collaboration

NMES may reduce muscle atrophy in patients with severe COPD: Researchers

Obese patients with COPD improve following pulmonary rehabilitation program: Research

Long-term, regular use of vitamin E in women may help decrease risk of COPD: Study

Researchers discover molecular mechanism behind smoking cessation effect

MediciNova announces $15 million senior secured term loan with Oxford Finance

Forest, Almirall to present data on aclidinium bromide for COPD and LAS100977 for asthma at ATS conference

Forest, Nycomed to present data from six roflumilast posters at ATS International Conference

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Chronic Obstructive Pulmonary Disease News and Research

Latest Chronic Obstructive Pulmonary Disease News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in